

Current M&A Pipeline

Project Alchemy

Sell-Side Advisory

Compounding Pharmacy

Acquisition opportunity of national 503A compounding pharmacy

Project Seminole

Sell-Side Advisory

Consumer Health

Acquisition opportunity of a foodservice and distribution company

Project Pacer

Sell-Side Advisory

Pharma

Acquisition opportunity of a specialty US generics business

Project Skyfall

Capital Raise

Pharma

Investment opportunity in commercial stage biopharma company

Project Genesis

Sell-Side Advisory

Behavioral Health

Acquisition opportunity of a Substance Use Disorder (SUD) treatment company

Project Trident

Buy-Side Advisory

Pharma

Seeking generic liquids or established brands across all formats sold through the hospital / institutional channel

Select Transactions

Nicox | Soleus Capital



Biopharma | Royalty Monetization

\$16.5 million - October 2024

Bourne Partners served as the exclusive financial advisor to Nicox on its \$16.5 million royalty monetization transaction with Soleus Capital

Nivagen Pharmaceuticals | MedisourceRx | Hims & Hers



Compounding | Sell-Side M&A Advisory

Undisclosed - September 2024

Bourne Partners served as the exclusive financial advisor to Nivagen Pharmaceuticals on the divestiture of its MedisourceRx business unit to Hims & Hers.

Ampersand Capital Partners | BPSC | MedPharm



CDMO | Strategic Capital

Undisclosed - March 2024

Bourne Partners Strategic Capital partnered with Ampersand Capital Partners and Pat Walsh and invested in MedPharm.

Reverba | 424 Capital | Six Degrees Worldwide



Pharmaceutical | Buy-Side M&A Advisory

Undisclosed - April 2024

Bourne Partners advised Reverba, a portfolio company of 424 Capital, on the acquisition of Six Degrees Worldwide.

American Injectables | New Rhein Healthcare Investors



Pharma Services | Financing

Undisclosed - February 2024

Bourne Partners served as the exclusive financial advisor to American Injectables in securing its Series B Financing from a consortium of investors led by New Rhein Healthcare Investors.

Afton Scientific | Arlington Capital Partners



Pharma Services | Sell-Side M&A Advisory

Undisclosed - January 2024

Bourne Partners served as the exclusive financial advisor to Afton Scientific in its majority investment from Arlington Capital Partners.

Summit Biosciences | Kindeva Drug Delivery



Pharma Services | Sell-Side M&A Advisory

Undisclosed - January 2024

Bourne Partners served as the exclusive financial advisor to Summit Biosciences in its sale to Kindeva Drug Delivery.

Clinclierge | Greenphire | Thoma Bravo



Pharma Services | Sell-Side M&A Advisory

Undisclosed - January 2024

Bourne Partners served as the exclusive financial advisor to Clinclierge in its sale to Greenphire, a portfolio company of Thoma Bravo.